Okay, let's tackle this question. The user is asking about the newer inclusions in the 2015 WHO classification of squamous cell carcinoma of the lung. First, I need to recall the WHO classifications for lung cancer. The WHO periodically updates their classifications based on new research. The 2015 edition was significant for lung cancer, especially in terms of subtypes and molecular features.

Squamous cell carcinoma is a type of non-small cell lung cancer (NSCLC). The 2015 WHO classification introduced several changes. One key addition was the inclusion of molecular subtypes, such as those with mutations in the TP53 gene, which is commonly associated with squamous cell carcinoma. Also, the classification started emphasizing the importance of PD-L1 expression, which is relevant for immunotherapy decisions. Another point is the distinction between keratinizing and non-keratinizing subtypes, but I need to check if that's a newer addition.

Wait, the 2015 WHO classification might have incorporated more detailed histological subtypes. For example, it could have added specific subtypes based on histology, like the presence of specific markers or genetic alterations. The 2015 update also integrated the concept of precursor lesions, such as squamous cell metaplasia with dysplasia, leading to carcinoma in situ. Additionally, the role of next-generation sequencing (NGS) in identifying actionable mutations like EGFR, ALK, ROS1, and BRAF became more prominent, though these might be more related to adenocarcinoma. However, for squamous cell carcinoma, maybe the inclusion of specific mutations like TP53 or CDKN2A is more relevant.

The options provided are A, B, C, D, but they are empty. However, the correct answer is supposed to be the newer inclusions. Common distractors might include older classifications or features from other subtypes. For example, if an option mentions small cell carcinoma, that's a different type. Another might refer to the 2011 classification, which focused on molecular subtypes in adenocarcinoma. The 2015 update for squamous cell carcinoma would include molecular features, histological subtypes, and precursor lesions.

Clinical pearls here would be to remember that the 2015 WHO classification for squamous cell carcinoma emphasizes molecular profiling and histological subtyping, which are crucial for treatment planning. Also, PD-L1 expression is part of this classification for determining immunotherapy eligibility. The key takeaway is that the 2015 edition added molecular markers and precursor lesion classifications for squamous cell carcinoma.

**Core Concept**
The 2015 WHO classification of lung cancer updated criteria for squamous cell carcinoma (SCC) to include molecular and histological subtypes, emphasizing PD-L1 expression, TP53 mutations, and precursor lesions like squamous cell metaplasia with dysplasia. This reflects advances in understanding SCC pathogenesis and treatment.

**Why the Correct Answer is Right**
The 2015 WHO classification introduced **molecular subtyping** (e.g., TP53 mutations) and **histological subtypes** (keratinizing vs. non-keratinizing SCC), along with **precursor lesions** such as squamous cell metaplasia with dysplasia. PD-L1 expression was

✓ Correct Answer: D. Nonkeratinizing variant